• Home Dutch
  •  EN 
  • Employee login

Experimental focus


Projects from the section of Experimental Pharmacology are directed at identification of novel drug targets, developing new chemical entities to modulate these and to investigate methods to optimize existing drug therapies.

Experiments are performed in a range of model systems (cellular, animals), dealing with highly fundamental cell processes, such as quality control of proteins, energy metabolism and cellular damage pathways. Application of this knowledge is sought primarily in the area of cardiac, vascular and renal disease or complications of disease (particularly diabetes).

Research in the past years has generated fundamental insights in processes, which have been claimed in patents. From this research line and based on obstained patents, 2 Groningen-based spin-off companies have emerged (Nyken b.v., Sulfateq b.v.) that have performed lead optimization and currently hold a pipeline of active compounds being explored in various conditions. Close interaction with the department is still ongoing on a number of projects

Organ damage and the role of CBS in hibernation.
Mechanisms and modulation of the immune response in sterile sepsis.
The CBS/H2S pathway in the brain.
Platelet dynamics in natural and pharmacologically induced hibernation.
Liver fibrosis and hibernation.
Towards prevention of neuroinflammation in major surgery.
Limiting the impact of stroke.
Identification of kinomic key proteins involved in tachycardia and stretch induced cardiomyocyte remodeling.
Role of epigenetic regulation by histone acetylation in the induction of Atrial Fibrillation.
Reversal of cardiomyocyte remodeling in Atrial Fibrillation; the role of protein degradation and translation modulators.
REVersal of cardiomyocyte structural remodeling and Improvement of functional recoVEry in Atrial Fibrillation: REVIVE.
HSF1 Activators Lower cardiomyocyte damage: towards a novel Therapeutic approach to REVERSE Atrial Fibrillation. HALT&REVERSE
Mutations in HSPB5, HSPB7 and BAG3 lead to juvenile DCM.
New therapeutic targets in diabetic kidney disease. A role of GDF-15?
Role of cyclooxygenase signalling on vascular dysfunction in the metabolic syndrome.
Vascular (Dys-)Function as a Determinant of Susceptibility to Diabetic Nephropathy: a Focus on Myogenic Constriction.